Stock Track | ImmunityBio Soars 6.39% Post-Market on Strong Revenue Growth and Anktiva Sales Surge

Stock Track

Feb 26

ImmunityBio, Inc. (NASDAQ:IBRX) shares soared 6.39% in post-market trading on Wednesday, following the release of impressive financial results and operational updates.

The biotechnology company reported a fivefold year-over-year revenue increase, with sales jumping to $38.29 million, surpassing analyst expectations. A key driver was a remarkable 750% increase in unit sales volume for its lead drug, Anktiva, which is approved for the treatment of non-muscle invasive bladder cancer in 33 countries.

Further supporting the positive sentiment, ImmunityBio announced a strategic partnership with Biopharma and Cigalah to commercialize and distribute Anktiva in Saudi Arabia and the broader Middle East and North Africa region. The company is also preparing to submit additional information to the U.S. Food and Drug Administration regarding Anktiva, indicating ongoing regulatory progress.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1187281056"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1187281056\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1187281056?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 09:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187281056","market":"sg","top_or_hot":-1,"title":"Stock Track | ImmunityBio Soars 6.39% Post-Market on Strong Revenue Growth and Anktiva Sales Surge","media":"Stock Track","content":"<p>ImmunityBio, Inc. (NASDAQ:IBRX) shares soared 6.39% in post-market trading on Wednesday, following the release of impressive financial results and operational updates.</p><p>The biotechnology company reported a fivefold year-over-year revenue increase, with sales jumping to $38.29 million, surpassing analyst expectations. A key driver was a remarkable 750% increase in unit sales volume for its lead drug, Anktiva, which is approved for the treatment of non-muscle invasive bladder cancer in 33 countries.</p><p>Further supporting the positive sentiment, ImmunityBio announced a strategic partnership with Biopharma and Cigalah to commercialize and distribute Anktiva in Saudi Arabia and the broader Middle East and North Africa region. The company is also preparing to submit additional information to the U.S. Food and Drug Administration regarding Anktiva, indicating ongoing regulatory progress.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ImmunityBio Soars 6.39% Post-Market on Strong Revenue Growth and Anktiva Sales Surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ImmunityBio Soars 6.39% Post-Market on Strong Revenue Growth and Anktiva Sales Surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-26 09:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ImmunityBio, Inc. (NASDAQ:IBRX) shares soared 6.39% in post-market trading on Wednesday, following the release of impressive financial results and operational updates.</p><p>The biotechnology company reported a fivefold year-over-year revenue increase, with sales jumping to $38.29 million, surpassing analyst expectations. A key driver was a remarkable 750% increase in unit sales volume for its lead drug, Anktiva, which is approved for the treatment of non-muscle invasive bladder cancer in 33 countries.</p><p>Further supporting the positive sentiment, ImmunityBio announced a strategic partnership with Biopharma and Cigalah to commercialize and distribute Anktiva in Saudi Arabia and the broader Middle East and North Africa region. The company is also preparing to submit additional information to the U.S. Food and Drug Administration regarding Anktiva, indicating ongoing regulatory progress.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1187281056","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187281056","pubTimestamp":1772067768,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ImmunityBio, Inc. (NASDAQ:IBRX) shares soared 6.39% in post-market trading on Wednesday, following the release of impressive financial results and operational updates.The biotechnology company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"个股追踪|ImmunityBio盘后大涨6.39%营收强劲增长Anktiva销量大增","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"ImmunityBio, Inc. (NASDAQ:IBRX) shares soared 6.39% in post-market trading on Wednesday, following the release of impressive financial results and operational updates.The biotechnology company reported a fivefold year-over-year revenue increase, with sales jumping to $38.29 million, surpassing analyst expectations. A key driver was a remarkable 750% increase in unit sales volume for its lead drug, Anktiva, which is approved for the treatment of non-muscle invasive bladder cancer in 33 countries.Further supporting the positive sentiment, ImmunityBio announced a strategic partnership with Biopharma and Cigalah to commercialize and distribute Anktiva in Saudi Arabia and the broader Middle East and North Africa region. The company is also preparing to submit additional information to the U.S. Food and Drug Administration regarding Anktiva, indicating ongoing regulatory progress.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}